Menu
Logo

METASTASIS-FREE SURVIVAL*1

72

*nmCRPC with a PSA doubling time of ≤10 months despite ADT.

REFERENCE
1- Smith MR, et al. N Engl J Med. 2018;378:1408–18.

erleada_logo

CP-142079